R&D
‘Respect for Human Life’ and ‘Value Creation’ are two core values that are important to Hanmi,
and we uphold them via our scientific research and achievements. Hanmi continues to show the highest
R&D investment-to-revenue among listed healthcare companies in Korea.
R&D
‘Respect for Human Life’ and ‘Value Creation’ are two core values that are important to Hanmi,
and we uphold them via our scientific research and achievements. Hanmi continues to show the highest
R&D investment-to-revenue among listed healthcare companies in Korea.

Overview

Hanmi recognized as the No.1 R&D investing company in Korea, developing next generation Platform Technologies & new drugs on the fields of oncology, metabolic disorders and rare diseases. Hanmi has worked closely with global partners on various co-developments and collaborations.
We are continuing to further expand through "Open Innovation Strategy" by finding potential partners for innovative solutions.

No.1 R&D Investing Company in Korea
No.1 R&D Investing Company in Korea
25% R&D staff
of total employees
500+ experts in pharmaceutical research
Over 500+ experts from 6 R&D Centers in Korea and China are expanding innovative pipelines
15% of sales
invested in R&D
Sustained R&D investment
Strong commitment in R&D supported by investment Multi-angle approach powered by strong internal R&D capacity
30+ Innovative
R&D assets
Powerful momentum for successful open innovation
Combine internal & external expertise for successful R&D collaboration and to focus on patient-centered R&D across multiple therapeutic areas